Idiopathic Pulmonary Fibrosis – Landscape & Forecast – Disease Landscape & Forecast
Idiopathic pulmonary fibrosis (IPF), one of the most common interstitial lung diseases, is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT) approved for IPF, followed soon after by Boehringer Ingelheim’s nintedanib (Ofev). These therapies set the stage for fierce competition in the IPF therapy market. We explore this evolving space by examining current medical practice, including the clinical and commercial outlook for pirfenidone and nintedanib; identifying the areas of pressing unmet need in the treatment of IPF; and assessing emerging therapies, including FibroGen’s IV-administered pamrevlumab, Roche’s IV-administered PRM-151, and United Therapeutics’ inhaled treprostinil.
QUESTIONS ANSWERED
- How will the size of the IPF population change through 2031? How large are the key subpopulations? What percentage of the IPF population receives drug treatment?
- How do interviewed experts view the clinical profiles of Esbriet and Ofev, and what factors drive or constrain their use? What are the most pressing unmet clinical needs in the management of IPF, according to experts?
- Which emerging therapies do IPF experts consider most promising? If approved, how would emerging therapies influence the management of IPF and the market position of Ofev and Esbriet? What is the commercial potential of pamrevlumab, PRM-151, and treprostinil?
PRODUCT DESCRIPTION
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research
SOLUTION ENHANCEMENT
Niche & Rare Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Idiopathic Pulmonary Fibrosis - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Idiopathic pulmonary fibrosis - Key findings
- Commercial outlook
- Key findings
- Regional sales of key therapies to treat IPF: 2021 and 2031
- IPF SWOT analysis
- Drivers and constraints
- What factors are driving the market for IPF?
- What factors are constraining the market for IPF?
- Drug-class-specific trends
- Antifibrotics
- Tyrosine kinase inhibitors
- Connective tissue growth factor inhibitors
- Recombinant human pentraxin-2 proteins
- Prostacyclin vasodilators
- Key findings
- Forecast
- Forecast sales of key therapies in idiopathic pulmonary fibrosis
- Etiology and pathophysiology
- Disease overview
- Etiology
- Key risk factors associated with idiopathic pulmonary fibrosis
- The lung in IPF
- Pathophysiology
- Role of inflammation
- Pathogenesis of IPF
- Disease progression
- Characteristics of rapid, moderate, and slow progressors
- Disease staging
- The GAP index
- Symptoms and complications
- Symptoms and complications of IPF
- Key symptoms and complications of IPF
- Key pathways and drug targets
- Key pathways and drug targets in IPF
- Key pathways and drug targets in IPF
- Epidemiology overview
- Key findings
- Epidemiology populations
- Disease definition
- Methods and sources used
- Number of diagnosed prevalent cases of IPF in the major pharmaceutical markets: 2021-2031
- Disease definition
- Methods and Sources Used
- Number of diagnosed prevalent cases of IPF in the major pharmaceutical markets by GAP severity: 2021-2031
- Disease definition
- Methods and sources used
- Number of diagnosed prevalent cases of IPF in the major pharmaceutical markets by comorbidity: 2021-2031
- Sources used for drug-treated prevalent cases of IPF
- Number of diagnosed and drug-treated prevalent cases of IPF: 2021-2031
- Key findings
- Current treatment overview
- Key findings
- Diagnosis
- Diagnosis of IPF
- Diagnostic tests and criteria
- Diagnostic criteria for IPF
- Comparison of ATS/ERS/JRS/ALAT recommendations for the diagnosis of IPF in 2011 and 2018
- Expert insight on diagnosis
- Treatment goals
- Key endpoints used in clinical trials for IPF
- Key current therapies
- Overview
- Mechanism of action of current drugs used for IPF
- Current treatments used for IPF
- Market events impacting the use of current therapies in IPF
- Clinical trial outcomes for pirfenidone
- Key results from select clinical trials investigating pirfenidone for the treatment of IPF
- Advantages and disadvantages of pirfenidone
- Recent clinical development of pirfenidone
- Recent trials of pirfenidone in the treatment of IPF
- Expert insight: pirfenidone
- Clinical trial outcomes for nintedanib
- Key results from select clinical trials investigating nintedanib for the treatment of IPF
- Advantages and disadvantages of nintedanib
- Ongoing clinical development
- Key ongoing trials of nintedanib in the treatment of IPF
- Expert insight on nintedanib
- Combination of pirfenidone and nintedanib
- Clinical trial outcomes for the combination of pirfenidone and nintedanib
- Key results from select clinical trials investigating the combination of pirfenidone and nintedanib for the treatment of IPF
- Key ongoing trials of the combination of pirfenidone and nintedanib in the treatment of IPF
- Expert insight on the combination of pirfenidone and nintedanib
- Other medications used to treat IPF
- Medical practice
- Overview
- IPF treatment guidelines
- Factors influencing drug selection in IPF
- Treatment providers
- Treatment initiation
- Treatment of severe IPF
- Expert insight on approach to treatment
- Expert insight on the role of specialty centers for IPF
- Generalized treatment decision tree for IPF
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in IPF
- Top unmet needs in IPF: current and future attainment
- Expert insight on the unmet needs in the treatment of IPF
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies overview
- Introduction
- Key findings
- Key emerging therapies
- Estimated launch dates of key emerging therapies for the treatment of IPF
- Key ongoing trials of pamrevlumab in the treatment of IPF
- Pamrevlumab clinical development
- Expert insight: Pamrevlumab
- Expectations for launch and sales opportunity of pamrevlumab in IPF
- PBI-4050 profile
- PBI-4050 clinical development
- Expectations for launch and sales opportunity of PBI-4050 in IPF
- PRM-151 profile
- Key ongoing trials of PRM-151 in the treatment of IPF
- PRM-151 clinical development
- Expert insight: PRM-151
- Expectations for launch and sales opportunity of PRM-151 in IPF
- Key ongoing clinical trials of treprostinil (inhaled) in the treatment of IPF
- Treprostinil (inhaled) clinical development
- Expert insight: treprostinil (inhaled)
- Expectations for launch and sales opportunity of treprostinil (inhaled) in IPF
- Early-phase pipeline analysis
- Select compounds in early-phase development for IPF
- Symptomatic or acute therapy in development for IPF
- Select symptomatic or acute therapies in early-phase development for IPF
- Key discontinuations and failures in IPF
- Key development discontinuations and failures
- Patient registries
- Patient registries for IPF
- Prominent patient organizations
- Orphan drug designation
- Introduction
- Access and reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in IPF: United States
- General reimbursement environment: United States
- Key market access considerations in IPF: EU5
- General reimbursement environment: EU5
- Region-specific reimbursement practices
- Appendix
- Key abbreviations related to IPF
- Brands, marketers, and generic availability of key therapies for IPF by market
- IPF bibliography
- Key findings
Anwesh Panda, M.Tech., is an analyst on the Infectious, Niche, & Rare Diseases (INRD) team at Clarivate. In this role, he conducts primary and secondary research on a range of indications. Prior to joining Clarivate, he was a market research analyst at Infiniti Research and Grand View Research. He holds a master’s degree in biotechnology from the Kiit School of Biotechnology in Odisha, India.
Mohani Latwal, B.P.T., M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, she worked as a deputy manager at an NGO. She received her bachelor’s degree in physiotherapy from Delhi University and her master’s degree in public health with a specialization in social epidemiology from the Tata Institute of Social Sciences in Mumbai.